NCT02653482

Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart Failure

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 263 (actual)
• Sponsor: Saint Luke's Health System · Academic / Other
• Sex: All
• Age: 19 Years – 119 Years
• Healthy volunteers: Not accepted

Summary

The primary purpose of this study is to evaluate the impact of dapagliflozin, as compared with placebo, on heart failure disease-specific biomarkers, symptoms, health status, and quality of life in patients with chronic heart failure with reduced systolic function.

Detailed description

A 12-week randomized, double-blind, placebo-controlled trial to evaluate the effects of once-daily dapagliflozin 10 mg on heart failure disease-specific biomarkers (BNP and NTproBNP), symptoms, health status, and quality of life in patients with chronic heart failure with reduced systolic function.

Conditions

• Chronic Heart Failure With Reduced Systolic Function

Interventions

Type	Name	Description
DRUG	Dapagliflozin
DRUG	Dapagliflozin matching placebo

Timeline

• Start date: 2016-03-03
• Primary completion: 2019-06-28
• Completion: 2019-06-28
• First posted: 2016-01-12
• Last updated: 2022-04-21
• Results posted: 2021-12-01

Locations

25 sites across 1 country: United States